Complement Therapeutics GmbH is a German headquartered biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. Their lead product is an innovative AAV gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry age-related macular degeneration (dry-AMD). The company aspires to transform the treatment landscape of GA and lower the treatment burden among patients through a “one and done” approach.
Year of investment
2023
Sector
Drug development
Location
Munich, Germany / Stevenage, UK
Website
http://complementtx.com